| Literature DB >> 34267484 |
Yutaro Wada1, Hajime Monzen2, Mikoto Tamura2, Masakazu Otsuka2, Masahiro Inada1, Kazuki Ishikawa1, Hiroshi Doi1, Kiyoshi Nakamatsu1, Yasumasa Nishimura1.
Abstract
PURPOSE: We investigated the performance of the simplified knowledge-based plans (KBPs) in stereotactic body radiotherapy (SBRT) with volumetric-modulated arc therapy (VMAT) for lung cancer.Entities:
Keywords: Knowledge-based plan; non-small cell lung cancer; plan quality; stereotactic body radiotherapy
Year: 2021 PMID: 34267484 PMCID: PMC8240912 DOI: 10.4103/jmp.JMP_67_20
Source DB: PubMed Journal: J Med Phys ISSN: 0971-6203
Patients’ characteristics in the training set, closed-loop validation group, and open-loop validation group
| Characteristics | Database ( | Closed-loop ( | Open-loop ( |
|---|---|---|---|
| Age, years | |||
| Median (range) | 76 (64-91) | 77 (66-91) | 78 (64-90) |
| Gender | |||
| Male | 35 | 9 | 9 |
| Female | 15 | 10 | 7 |
| Tumor location | |||
| Right | 31 | 10 | 12 |
| Upper lobe | 10 | 4 | 6 |
| Middle lobe | 5 | 1 | 1 |
| Lower lobe | 12 | 4 | 5 |
| Resection stump | 4 | 1 | 0 |
| Left | 19 | 9 | 4 |
| Upper lobe | 12 | 7 | 3 |
| Middle lobe | 2 | 1 | 0 |
| Lower lobe | 3 | 1 | 1 |
| Resection stump | 2 | 0 | 0 |
| Stage | |||
| Primary lung cancer | |||
| T1a | 4 | 2 | 0 |
| T1b | 20 | 9 | 6 |
| T1c | 5 | 2 | 4 |
| T2a | 7 | 1 | 5 |
| T2b | 2 | 2 | 0 |
| Postoperative recurrence | 9 | 1 | 0 |
| Metastasis | 3 | 2 | 1 |
| PTV volume (cm2) | |||
| Median | 37.2 | 29.5 | 31.3 |
| Range | 11.2-190.7 | 12.2-190.7 | 10.7-97.3 |
PTV: Planning target volume
Dosimetric constraints of planning target volume and organs at risk based on Japan clinical oncology group trial 1408
| Dose-volume parameter | Constraint |
|---|---|
| PTV | |
| Dmax | ≤120%-140% |
| Dmean | ≒108% |
| Dmin | ≥94% |
| Total lung | |
| Dmean | ≤18 Gy |
| Volume receiving ≥15 Gy (V15 Gy) | ≤25% |
| Volume receiving ≥20 Gy (V20 Gy) | ≤20% |
| Volume receiving ≥40 Gy (V40 Gy) | ≤100 cm3 |
| Spinal cord (PRV) | |
| Dmax | ≤25 Gy |
| Esophagus | |
| Volume receiving ≥40 Gy (V40Gy) | ≤1 cm3 |
| Volume receiving ≥35 Gy (V35Gy) | ≤10 cm3 |
| Heart | |
| Volume receiving ≥30 Gy (V30Gy) | ≤15 cm3 |
PTV: Planning target volume, PRV: Planning organ at risk volume, Dmax: Maximum dose, Dmean: Mean dose, Dmin: Minimum dose
Figure 1Schema of the validation method. (a) Closed-loop validation based on 19 volumetric-modulated arc therapy plans: clinical plan (CLP) vs. knowledge-based plan using the TrueBeam (KBPclosed-TB) vs. Halcyon (KBPclosed-Hal) for the cases enrolled in the database. (b) Open-loop validation based on 16 volumetric-modulated arc therapy plans: CLP vs. knowledge-based plan using the TrueBeam (KBPopen-TB) vs. Halcyon (KBPopen-Hal) for the cases not enrolled in the database
Model objectives and priorities
| Structure | Objective type | Relative volume (%) | Relative dose (%) | Priority |
|---|---|---|---|---|
| PTV | Upper | 0 | 120 | 100 |
| Lower | 100 | 94 | 100 | |
| Total lung−PTV | Line | Generated | Generated | Generated |
| Spinal cord | Line | Generated | Generated | Generated |
PTV: Planning target volume
Comparison of dose-volume parameters of the planning target volume, lung, spinal cord (PRV), and monitor unit between the clinical plan, knowledge-based plan closed-TrueBeam, and knowledge-based plan closed-Halcyon
| CLP | KBPclosed-TB | KBPclosed-Hal | ||||
|---|---|---|---|---|---|---|
| CLP vs. KBPclosed-TB | CLP vs. KBPclosed-Hal | KBPclosed-TB vs. KBPclosed-Hal | ||||
| PTV | ||||||
| D2% (Gy) | 57.01±2.28 | 58.50±1.51 | 59.12±1.72 | 0.08 | 0.004 | 0.34 |
| D50% (Gy) | 51.97±1.02 | 53.25±0.78 | 53.87±1.08 | <0.001 | <0.001 | 0.02 |
| D98% (Gy) | 47.39±0.45 | 47.26±0.45 | 47.10±0.19 | 0.01 | 0.002 | 0.29 |
| HI | 18.49±4.29 | 21.09±2.83 | 22.27±3.14 | 0.07 | 0.004 | 0.19 |
| CI95 | 1.32±0.12 | 1.18±0.09 | 1.17±0.06 | <0.001 | <0.001 | 0.88 |
| Total lung | ||||||
| Dmean (Gy) | 3.33±1.55 | 3.31±1.44 | 3.34±1.43 | 0.90 | 0.99 | 0.93 |
| V40 (cm3) | 22.25±15.89 | 13.64±6.58 | 13.27±6.27 | 0.04 | 0.04 | 0.98 |
| V20 (%) | 4.36±2.87 | 3.54±1.95 | 3.54±1.94 | 0.54 | 0.54 | 0.99 |
| V15 (%) | 6.40±3.97 | 5.45±2.78 | 5.68±3.01 | 0.70 | 0.87 | 0.80 |
| V5 (%) | 15.57±7.11 | 19.41±9.68 | 19.25±9.39 | 0.27 | 0.30 | 0.88 |
| Ipsilateral lung | ||||||
| Dmean (Gy) | 5.73±2.68 | 5.16±2.01 | 5.23±2.06 | 0.68 | 0.74 | 0.82 |
| V20 (%) | 9.32±6.34 | 7.36±3.98 | 7.37±4.05 | 0.46 | 0.40 | 0.99 |
| V5 (%) | 28.94±11.54 | 28.25±10.56 | 28.75±10.79 | 0.77 | 0.93 | 0.84 |
| Contralateral lung | ||||||
| Dmean (Gy) | 1.13±0.65 | 1.55±0.96 | 1.53±0.92 | 0.15 | 0.13 | 0.95 |
| V20 (%) | 0.0 | 0.0 | 0.0 | 1 | 1 | 1 |
| V5 (%) | 2.43±4.19 | 10.41±10.81 | 9.43±10.13 | 0.002 | 0.007 | 0.73 |
| Spinal cord (PRV) | ||||||
| Dmax (Gy) | 11.78±6.45 | 11.99±3.71 | 11.62±4.61 | 0.34 | 0.90 | 0.35 |
| Heart | ||||||
| V30 (cm3) | 1.32±4.14 | 1.61±5.93 | 1.48±5.39 | 0.65 | 0.87 | 0.99 |
| Esophagus | ||||||
| V35 (cm3) | 0.0 | 0.0 | 0.0 | 1 | 1 | 1 |
| V40 (cm3) | 0.0 | 0.0 | 0.0 | 1 | 1 | 1 |
| R50 | 5.03±0.91 | 4.31±0.72 | 4.27±0.66 | 0.007 | 0.003 | 0.95 |
| MU | 3067.10±511.80 | 4285.60±608.97 | 3295.02±323.71 | <0.001 | 0.18 | <0.001 |
PTV: Planning target volume, PRV: Planning organ at risk volume, MU: Monitor unit, CLP: Clinical plan, KBP: Knowledge-based plan, TB: TrueBeam, Hal: Halcyon, Dmean: Mean dose, Dmax: Maximum dose
Comparison of dose-volume parameters of the planning target volume, lung, spinal cord (PRV), and monitor unit between the clinical plan, knowledge-based plan open-TrueBeam, and knowledge-based plan open-Halcyon
| CLP | KBPopen-TB | KBPopen-Hal | ||||
|---|---|---|---|---|---|---|
| CLP vs. KBPopen-TB | CLP vs. KBPopen-Hal | KBPopen-TB vs. KBPopen-Hal | ||||
| PTV | ||||||
| D2% (Gy) | 59.63±2.77 | 58.98±0.93 | 59.44±1.07 | 0.34 | 0.85 | 0.17 |
| D50% (Gy) | 52.84±1.20 | 53.55±0.53 | 53.83±0.47 | 0.02 | 0.007 | 0.13 |
| D98% (Gy) | 46.91±0.70 | 47.21±0.14 | 47.20±0.12 | 0.36 | 0.40 | 0.82 |
| HI | 23.98±5.40 | 21.96±1.71 | 22.72±1.97 | 0.16 | 0.36 | 0.24 |
| CI95 | 1.22±0.09 | 1.14±0.04 | 1.16±0.05 | 0.003 | 0.01 | 0.56 |
| Total lung | ||||||
| Dmean (Gy) | 3.08±0.69 | 3.12±0.66 | 3.17±0.71 | 0.75 | 0.78 | 0.72 |
| V40 (cm3) | 17.70±12.38 | 13.46±6.75 | 14.05±6.48 | 0.22 | 0.40 | 0.58 |
| V20 (%) | 4.18±1.57 | 3.55±1.27 | 3.67±1.26 | 0.19 | 0.27 | 0.81 |
| V15 (%) | 6.36±2.17 | 5.73±1.89 | 5.84±1.86 | 0.35 | 0.58 | 0.65 |
| V5 (%) | 15.03±3.70 | 17.03±3.43 | 17.36±3.87 | 0.09 | 0.08 | 0.52 |
| Ipsilateral lung | ||||||
| Dmean (Gy) | 5.02±1.22 | 4.72±1.17 | 4.85±1.19 | 0.51 | 0.73 | 0.66 |
| V20 (%) | 7.81±2.83 | 6.58±2.23 | 6.80±2.20 | 0.17 | 0.25 | 0.69 |
| V5 (%) | 26.63±7.27 | 26.13±7.28 | 26.61±7.68 | 0.78 | 0.99 | 0.72 |
| Contralateral lung | ||||||
| Dmean (Gy) | 0.82±0.31 | 1.23±0.40 | 1.26±0.39 | 0.006 | 0.004 | 0.76 |
| V20 (%) | 0.0 | 0.0 | 0.0 | 1 | 1 | 1 |
| V5 (%) | 1.50±2.32 | 6.08±5.73 | 6.33±6.18 | 0.006 | 0.005 | 0.92 |
| Spinal cord (PRV) | ||||||
| Dmax (Gy) | 11.26±5.57 | 12.19±4.13 | 12.32±4.51 | 0.45 | 0.24 | 0.75 |
| Heart | ||||||
| V30 (cm3) | 0.0 | 0.0 | 0.0 | 1 | 1 | 1 |
| Esophagus | ||||||
| V35 (cm3) | 0.0 | 0.03±0.11 | 0.03±0.10 | 0.35 | 1 | 0.99 |
| V40 (cm3) | 0.0 | 0.002±0.01 | 0.004±0.01 | 0.35 | 1 | 0.99 |
| R50 | 4.79±0.71 | 4.16±0.53 | 4.35±0.72 | 0.008 | 0.09 | 0.49 |
| MU | 3527.94±655.43 | 4176.44±466.55 | 3311.17±290.15 | 0.003 | 0.57 | <0.001 |
PTV: Planning target volume, PRV: Planning organ at risk volume, MU: Monitor unit, CLP: Clinical plan, KBP: Knowledge-based plan, TB: TrueBeam, Hal: Halcyon, Dmean: Mean dose, Dmax: Maximum dose
Figure 2Example dose distributions for the clinical plan (CLP) and knowledge-based plans using the TrueBeam and Halcyon in open-loop validation (KBPopen-TB and KBPopen-Hal). Compared with the clinical plans, both the KBPopen-TB and KBPopen-Hal had more extended low-dose distribution but higher conformity to the planning target volume
Figure 3Comparisons of dose-volume parameters of the planning target volume between the clinical plans (CLPs) and knowledge-based plans (KBPs) using the TrueBeam and Halcyon in closed- and open-loop validations (KBPclosed-TB, KBPclosed-Hal, KBPopen-TB, and KBPopen-Hal, respectively). Central line of each box: median line; lower line: first quartile; upper line: third quartile. Whisker ranges do not contain outliers, which are plotted as individual points. N.S.; not significant, *P < 0.05, **P < 0.01, ***P < 0.001